AR044069A1 - Un metodo de diuresis mejorada en individuos con funcion renal deteriorada - Google Patents

Un metodo de diuresis mejorada en individuos con funcion renal deteriorada

Info

Publication number
AR044069A1
AR044069A1 ARP040101381A ARP040101381A AR044069A1 AR 044069 A1 AR044069 A1 AR 044069A1 AR P040101381 A ARP040101381 A AR P040101381A AR P040101381 A ARP040101381 A AR P040101381A AR 044069 A1 AR044069 A1 AR 044069A1
Authority
AR
Argentina
Prior art keywords
diuretic
individuals
renal function
metabolite
prodrug
Prior art date
Application number
ARP040101381A
Other languages
English (en)
Inventor
Scott Thomson
Kenneth J Widder
Lauren Otsuki
Roland Blantz
Howard C Dittrich
Original Assignee
Nova Cardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nova Cardia Inc filed Critical Nova Cardia Inc
Publication of AR044069A1 publication Critical patent/AR044069A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición farmacéutica que comprende una cantidad terapéuticamente efectiva de KW-3902, o una sal, éster, amida, metabolito o prodroga del mismo, y un diurético que no modifique la adenosina. Métodos para inducir un efecto diurético en un animal que comprenden el paso de administrar una cantidad terapéuticamente efectiva de KW-3902, o una sal, éster, amida, metabolito o prodroga del mismo, en combinación con una segunda composición farmacéutica capaz de inducir un efecto diurético. El KW- 3902 es un antagonista del receptor de adenosina A1 derivado de Xantina (AA1RA). Su nombre químico es 8-(3-noradamantil)-1,3-dipropilxantina, conocida también como 3,7-dihidro-1,3-dipropil-8-(3-triciclo[3.3.1.03,7]nonil)-1H-purina-2,6- diona. Reivindicación 5: La composición de acuerdo con la reivindicación 1, donde el diurético se selecciona dentro del grupo consistente en hidroclorotiazidas, furosemida, torsemida, bumetanida, ácido etacrínico, piretanida, norsemida, espironolactona, triamterene y amiloridetiazidas.
ARP040101381A 2003-04-25 2004-04-23 Un metodo de diuresis mejorada en individuos con funcion renal deteriorada AR044069A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46600703P 2003-04-25 2003-04-25

Publications (1)

Publication Number Publication Date
AR044069A1 true AR044069A1 (es) 2005-08-24

Family

ID=33418325

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101381A AR044069A1 (es) 2003-04-25 2004-04-23 Un metodo de diuresis mejorada en individuos con funcion renal deteriorada

Country Status (16)

Country Link
US (3) US7579331B2 (es)
EP (1) EP1620107A1 (es)
JP (1) JP2006524699A (es)
KR (1) KR20060004959A (es)
CN (1) CN1859913A (es)
AR (1) AR044069A1 (es)
AU (1) AU2004233852A1 (es)
BR (1) BRPI0409699A (es)
CA (1) CA2522971A1 (es)
MX (1) MXPA05011371A (es)
NO (1) NO20055536L (es)
NZ (1) NZ543109A (es)
RU (1) RU2367442C2 (es)
TW (1) TW200500070A (es)
WO (1) WO2004096228A1 (es)
ZA (1) ZA200509311B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
BRPI0409699A (pt) * 2003-04-25 2006-04-18 Novacardia Inc métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
CA2536975A1 (en) * 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
BRPI0509753A (pt) * 2004-04-16 2007-10-16 Novacardia Inc composição farmacêutica e método de tratamento de doença cardiovascular
WO2006091716A2 (en) * 2005-02-24 2006-08-31 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use
WO2006115690A2 (en) * 2005-04-22 2006-11-02 Novacardia, Inc. Production of emulsions for intravenous injection of water-insoluble pharmaceutical compositions
WO2007069675A1 (ja) * 2005-12-14 2007-06-21 Kyowa Hakko Kogyo Co., Ltd. キサンチン誘導体の易吸収性経口製剤
KR20080110776A (ko) * 2006-04-06 2008-12-19 노바카르디아, 인코포레이션 아데노신 ａ₁ 수용체 길항제 및 항경련제의 공동 투여
WO2007149283A2 (en) * 2006-06-16 2007-12-27 Novacardia, Inc. Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
CN101466383A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 包含低频率投与aa1ra的肾功能延长改善
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416810C (sv) 1977-10-14 1982-07-19 Draco Ab Forfarande for framstellning av xantinderivat med antiallergisk aktivitet
FR2531085A1 (fr) 1982-07-28 1984-02-03 Adir Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4769377A (en) * 1983-02-18 1988-09-06 The Johns Hopkins University Adenosine receptor antagonists
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
SE9000207L (sv) 1990-01-22 1991-07-23 Nobel Chemicals Ab Laekemedel samt anvaendningen av detsamma
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
WO1993000081A1 (en) 1991-06-28 1993-01-07 Sepracor, Inc. Optically pure s(-) nadolol for treatment of cardiovascular disorders
CA2093403C (en) 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
TW252044B (es) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
DE4238367A1 (de) * 1992-11-13 1994-05-19 Boehringer Ingelheim Kg Diuretisches Mittel
US5395836A (en) * 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
CN1049117C (zh) 1994-09-16 2000-02-09 赵明玉 预防和治疗偏头痛的偏头痛片
DE69628276T2 (de) * 1995-07-26 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. Zubereitung von xanthinderivaten als feste dispersion
DK0958821T3 (da) 1996-08-07 2005-01-03 Kyowa Hakko Kogyo Kk Fedtemulsion, der indeholder xanthinderivat
US6187780B1 (en) * 1998-04-16 2001-02-13 Boehringer Ingelheim Pharma Kg Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
DE19816857A1 (de) 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20020115687A1 (en) * 1998-04-24 2002-08-22 Evan Beckman Method and composition for restoring diuretic and renal function
JP2002506463A (ja) 1998-04-24 2002-02-26 バイオジェン，インコーポレイテッド 利尿機能および腎機能を回復するためのアデノシンａ１レセプターアンタゴニスト含有組成物および方法
EP0970696A1 (en) 1998-05-05 2000-01-12 Kyowa Hakko Kogyo Co., Ltd. Combination of loop diuretics with adenosine A1-receptor antagonists
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
SI1230243T1 (sl) * 1999-11-12 2009-08-31 Biogen Idec Inc Policikloalkilpurini kot antagonisti adenozinskega receptorja
JP2003513976A (ja) 1999-11-12 2003-04-15 バイオジェン インコーポレイテッド アデノシンレセプターアンタゴニストおよびこれを作製し使用する方法
US20050038017A1 (en) * 1999-12-22 2005-02-17 Wolff Andrew A. Method and composition for restoring diuretic and renal function
YU42903A (sh) * 2000-12-01 2006-05-25 Biogen Inc. Kondenzovani derivati purina kao antagonisti a1 receptora adenozina
IL156136A0 (en) 2000-12-18 2003-12-23 Novartis Ag Therapeutic combination of amlodipine and benazepril
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
BRPI0409699A (pt) 2003-04-25 2006-04-18 Novacardia Inc métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
BRPI0509753A (pt) * 2004-04-16 2007-10-16 Novacardia Inc composição farmacêutica e método de tratamento de doença cardiovascular
WO2005105803A2 (en) * 2004-04-28 2005-11-10 Cv Therapeutics, Inc. Purine derivatives as a1 adenosine receptor antagonists
KR20080110776A (ko) * 2006-04-06 2008-12-19 노바카르디아, 인코포레이션 아데노신 ａ₁ 수용체 길항제 및 항경련제의 공동 투여
WO2007149283A2 (en) * 2006-06-16 2007-12-27 Novacardia, Inc. Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
CN101466383A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 包含低频率投与aa1ra的肾功能延长改善
AU2007288312A1 (en) * 2006-08-22 2008-02-28 Novacardia, Inc. KW-3902 conjugates that do not cross the blood-brain barrier

Also Published As

Publication number Publication date
NO20055536L (no) 2005-12-29
NO20055536D0 (no) 2005-11-23
WO2004096228A1 (en) 2004-11-11
RU2367442C2 (ru) 2009-09-20
JP2006524699A (ja) 2006-11-02
US20050004145A1 (en) 2005-01-06
US20060035911A1 (en) 2006-02-16
MXPA05011371A (es) 2005-12-01
ZA200509311B (en) 2006-10-25
KR20060004959A (ko) 2006-01-16
RU2005131938A (ru) 2006-06-27
US20060030572A1 (en) 2006-02-09
CA2522971A1 (en) 2004-11-11
TW200500070A (en) 2005-01-01
CN1859913A (zh) 2006-11-08
US7579331B2 (en) 2009-08-25
AU2004233852A1 (en) 2004-11-11
BRPI0409699A (pt) 2006-04-18
EP1620107A1 (en) 2006-02-01
NZ543109A (en) 2008-06-30

Similar Documents

Publication Publication Date Title
AR044069A1 (es) Un metodo de diuresis mejorada en individuos con funcion renal deteriorada
De Sarro et al. Effects of adenosine receptor agonists and antagonists on audiogenic seizure-sensible DBA/2 mice
Corbin et al. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5)
Jacobson et al. Adenosine receptor ligands: differences with acute versus chronic treatment
Jacobson et al. A role for central A3-adenosine receptors: Mediation of behavioral depressant effects
Rogawski AMPA receptors as a molecular target in epilepsy therapy
Huang et al. Accumulation of cyclic adenosine monophosphate in incubated slices of brain tissue. 2. Effects of depolarizing agents, membrane stabilizers, phosphodiesterase inhibitors, and adenosine analogs
Maemoto et al. Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors
Abebe et al. Adenosine receptor-mediated relaxation of porcine coronary artery in presence and absence of endothelium
Mandhane et al. Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats
ES2128735T3 (es) Composiciones farmaceuticas que comprenden un antagonista de opiaceos y de sales de calcio y su uso para el tratamiento de patologias en las que intervienen las endorfinas.
Collins et al. Interactions between adenosine and dopamine receptor antagonists with different selectivity profiles: effects on locomotor activity
Prentice et al. Activation of multiple sites by adenosine analogues in the rat isolated aorta
Feoktistov et al. Inhibition of human mast cell activation with the novel selective adenosine A2B receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX)
CH669730A5 (es)
ATE497384T1 (de) Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
WO1998030900A2 (en) Screening method for compounds active in treating myopia and hypermetropia
Simon DMARDs in the treatment of rheumatoid arthritis: current agents and future developments
Asomoza-Espinosa et al. Sildenafil increases diclofenac antinociception in the formalin test
Zarrindast et al. Effects of adenosine receptor agonists and antagonists on acquisition of passive avoidance learning
CN113559104A (zh) 慢性咳嗽治疗用药物
Clark et al. Effect of acute ethanol on release of endogenous adenosine from rat cerebellar synaptosomes
Nikodijević et al. Characterization of the locomotor depression produced by an A2‐selective adenosine agonist
Campbell et al. Selective A1-adenosine receptor antagonists identified using yeast Saccharomyces cerevisiae functional assays
Baraldi et al. Recent developments in the field of A2A and A3 adenosine receptor antagonists

Legal Events

Date Code Title Description
FB Suspension of granting procedure